Key statistics
On Tuesday, Citius Pharmaceuticals Inc (47N:FRA) closed at 0.3832, 41.61% above the 52 week low of 0.2706 set on Nov 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.3832 |
---|---|
High | 0.3832 |
Low | 0.3832 |
Bid | 0.4266 |
Offer | 0.4738 |
Previous close | 0.3454 |
Average volume | 3.95k |
---|---|
Shares outstanding | 180.73m |
Free float | 168.42m |
P/E (TTM) | -- |
Market cap | 81.18m USD |
EPS (TTM) | -0.2443 USD |
Data delayed at least 15 minutes, as of Nov 12 2024 07:11 GMT.
More ▼
Press releases
- Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
- Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology